Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.31 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 1217
Sealed predictions
- SEC14L1 in dopamine neurons, braak-0.34 (p 0.367) → -0.37 (p 0.329)receipt 1224
Swarm cases
receipt 1224: SEC14L1 in dopamine neurons, braak
- power
- full sample -0.30 (p 0.225, n 18), 95% CI -0.67 to +0.19. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.185, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.137, n 18). could be the mix.
- skeptic
- leave-one-out range -0.39 to -0.21, sign flips 0; without severely affected donors -0.30 (p 0.225, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.73 (p 6.6e-4, n 18) vs -0.30 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SEC14L1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SEC14L1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 0.0011)
Receipts
loading the receipts